Acute Coronary Syndrome: Secondary Prevention | Treatment Algorithms: Claims Data Analysis | US | 2025

Acute coronary syndrome (ACS)—subtype of coronary artery disease (CAD)—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. This report focuses on the posthospital, secondary prevention of ACS aimed to prevent recurrent CV events, adverse cardiac remodeling, and prolong survival. The current ACS secondary prevention market is dominated by generic therapies. Branded options include the injectable PCSK9 inhibitors, Amgen’s Repatha (evolocumab) and Sanofi’s / Regeneron’s Praluent (alirocumab), and the oral antiplatelet agents, AstraZeneca’s Brilinta (ticagrelor) and Merck’s Zontivity (vorapaxar). In this report, we analyze how secondary prevention of ACS is being treated in the United States and provide insights into the factors driving current prescribing practices for newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ACS secondary prevention patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ACS secondary prevention patients?
• How have Repatha, Praluent, and Brilinta been integrated into the treatment algorithm, and what is its source of business?
• What percentage of ACS secondary prevention patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of ACS secondary prevention patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Amgen, Sanofi, Regeneron, AstraZeneca

Key drugs: Repatha, Praluent, Brilinta

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses